| Literature DB >> 31554154 |
Galina Hovhannisyan1, Tigran Harutyunyan2, Rouben Aroutiounian3, Thomas Liehr4.
Abstract
DNA copy number variation (CNV) occurs due to deletion or duplication of DNA segments resulting in a different number of copies of a specific DNA-stretch on homologous chromosomes. Implications of CNVs in evolution and development of different diseases have been demonstrated although contribution of environmental factors, such as mutagens, in the origin of CNVs, is poorly understood. In this review, we summarize current knowledge about mutagen-induced CNVs in human, animal and plant cells. Differences in CNV frequencies induced by radiation and chemical mutagens, distribution of CNVs in the genome, as well as adaptive effects in plants, are discussed. Currently available information concerning impact of mutagens in induction of CNVs in germ cells is presented. Moreover, the potential of CNVs as a new endpoint in mutagenicity test-systems is discussed.Entities:
Keywords: animal and plant cells; chemical mutagens; copy number variation; human; radiation
Mesh:
Substances:
Year: 2019 PMID: 31554154 PMCID: PMC6801639 DOI: 10.3390/ijms20194723
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Summary of studies on induction of copy number variations (CNVs) using radiation and chemical mutagens in vitro with selected examples of deletion and duplication loci. NA = not applicable.
| Mutagen | Cells | Chromosomes Most Frequently Involved in Gains | Chromosomes Most Frequently Involved in Losses | Prevailing CNV in the Genome | Reference |
|---|---|---|---|---|---|
| γ-radiation | Human lymphoblastoid cell line TK6 | 3q, 13q and 20q | X | Gain | [ |
| X-ray | Human lung cancer cell line A549 | 3 and 5 | X, 3 and 5 | Loss | [ |
| X-ray | Human immortalized fibroblasts hTERT | 6p, 7q11.22, 9p and 16q23.1 | 3q13.31 and 15q | Gain | [ |
| X-ray | Primary human fibroblasts | 1q44 and 10q26.11 | 3p14.2, 7q11.2 and 7p12.1-7q11.1 | Loss | [ |
| Accelerated electrons | Human blood leukocytes | 7q11.22 and 9q21.3 | NA | Gain | [ |
| Aphidicolin | Normal human fibroblasts HGMDFN090 | 1q44, 7q21.11-q31.3, 10q25.2 and 15q22.2 | 3q26.3, 3q13.31, 10q11.23-q21.1 | Loss | [ |
| Aphidicolin | Human immortalized fibroblasts hTERT | 1, 9, 10 and 16 | 3, 7, 11, 13, 15 and 18 | Loss | [ |
| Hydroxyurea | Human immortalized fibroblasts hTERT | 1p36.31- 1q25.1 and 3p25.3- 3q27.3 | 3q13.31 and 7q11.22-7q33 | Loss | [ |
| EMS | Zebrafish fibroblast cell line | 13 and 20 | 5, 8 and 18 | Loss | [ |
| Cytosine arabinoside | Zebrafish fibroblast cell line | 5 | NA | Gain | [ |
| Aflatoxin B1 | Human blood leukocytes | NA | 8p21.2 and 15q11.2 | Loss | [ |
Summary of studies on induction of CNVs using radiation and chemical mutagens in vivo with selected examples of deletion and duplication loci. NA = not applicable.
| Mutagen | Organism and cells | Chromosomes/Genes Most Frequently Involved in Gains | Chromosomes/Genes Most Frequently Involved in Losses | Prevailing CNV in the Genome | Reference |
|---|---|---|---|---|---|
| γ-radiation | Rat mammary carcinoma | 1q12 | 3q35-q36, 5q32, and 7q11 | Loss | [ |
| γ-radiation | NF1 mutant mouse models of secondary malignant neoplasm | 1 | 11 | Loss | [ |
| γ-radiation | Wild-type mouse models of secondary malignant neoplasm | 1 | 5 and 11 | Gain | [ |
| Radium-226 | Human breast cancer | 2q, 4, 17, 21q, and 22q | 6q | Gain | [ |
| Ionizing radiation during Chernobyl accident | Human papillary thyroid carcinoma | 1p34, 1q21, 2p11.1-pter, 2q11.2-13, 3q26.2-26.3, 5q23-31, 6p21.3-pter, 7q11, 9q13-q33, 12q22-qter, 13q32-qter, 17q11.1-qter, 19, 20, and X | 1q42, 13q21, and 15q11.1-14 | Gain | [ |
| Ionizing radiation during Chernobyl accident | Human childhood thyroid tumors | 2, 7q11.2-21, 13q21-22, and 21 | 16p, 16q, 20q, and 22q | Gain | [ |
| Ionizing radiation during Chernobyl accident | Human childhood thyroid tumors | 19 and 21 | 1p36.31-35.3, 1p33-cen, 1q23.2-32.1, 6, 9p21.1-pter, 9q31.1, 9p23-q33.2, and 13 | Loss | [ |
| Ionizing radiation during Chernobyl accident | Human childhood thyroid tumors | 1p, 5p, 9q, 12q, 13q, 16p, 21q, and 22q | 1q, 6q, 9q, 10q, 13q, 14q, 21q, and 22q | NA | [ |
| Ionizing radiation during Chernobyl accident | Human breast cancer | 7q11.22-11.23, 7q21.3, 16q24.3, 17q21.31, and 20p11.23-11.21 | 1p21.1, 2q35, and 6p22.2 | Gain | [ |
| A-bomb | Human breast cancer | c-Myc, HER2 | NA | Gain | [ |
| Possibly solar UV radiation | Human whole blood | MMP12 | SDHD | Gain | [ |
| Possibly solar UV radiation | Human primary melanoma | GAB2, KIT | NA | Gain | [ |
| UV radiation | Mouse malignant melanoma | NA | Trp63, Pten | Loss | [ |
| Possibly solar UV radiation | Human melanocytic neoplasms | BRAF, NRAS, and MAP2K1 | NA | NA | [ |
| Asbestos | Human lung cancer | 2p21-p23 | 9p23-pter | Gain | [ |
| Asbestos | Human lung cancer | 2p21–p16.3 | 3p21.31, 5q35.2–q35.3, and 19pl3.3–p13.1 | Loss | [ |
| Asbestos | Human lung cancer | NA | 2p16 | Loss | [ |
| Arsenic | Human lung cancer | 19q13.33 | 1q21.1, 7p22.3, 9q12, and 19q13.31 | Loss | [ |
| Polychlorinated biphenyls and polybrominated diphenyl ethers | Human brain samples | 15q11q13 | NA | Gain | [ |
| Combination of doxorubicin, cyclophophamid and docetaxel | Human breast cancer | c-Myc | NA | Gain | [ |
| Bevacizumab plus neoadjuvant chemotherapy | Human breast cancer | 11q13.2 and 12p11.21 | 6p21.33-p21.3, 8p, 11q13.5-q25, 13q31-q34, and 19q13 | Loss | [ |
| FOLFOX | Human colorectal cancer | 7q21, 10q22, and 10q23 | NA | NA | 54 |
| Ozone in the air | Blood from patients with autism | NA | NA | Gain | [ |
| Radio- and chemotherapy | Human lung cancer | FGFR1 | CDKN2A | Gain | [ |
| γ-radiation | Mouse thymic lymphoma | 4, 5, and 15 | 11, 16, and 19 | NA | [ |
| N-methyl-N-nitrosourea | Mouse thymic lymphoma | 10, 14, and 15 | NA | NA | [ |
| γ-radiation | Murine soft-tissue sarcoma | NA | NA | Loss | [ |
| MCA | Murine soft-tissue sarcoma | NA | NA | Loss | [ |
| Vinclozolin | Murine germ cells | 2 and 9 | NA | Gain | [ |
| Benzo(a)pyrene | Murine germ cells | 3, 5 and 16 | 3 | Gain | [ |